Luneri

Taurine clinical brief

Taurine

Dossier liveB

Cardiovascular

CardiovascularStructured dossier pageDossier-backed

Compare alternatives Build protocol How this page is sourced

Evidence strength

High confidence

24 meta-analyses - 192 RCTs - 386 tracked studies

Evidence index71/100

Dossier-backed

This page is grounded in structured dossier fields, with deterministic summaries layered on top for readability.

What it is for

Type 2 diabetes mellitus and metabolic syndrome - glycemic, lipid, and inflammatory biomarker improvement

The clearest current human use case based on dose, outcomes, and clinical coverage.

What moves

Human linked

Highest-signal biomarkers

AST

Hepatic and liver

Decrease

Grade A

Lipid response

Decrease

Grade A

MDA

Oxidative stress

Decrease

Grade A

Research signal

Top caution

Insulin and insulin secretagogues (sulfonylureas, glinides)

Clinically meaningful in T2DM patients on insulin or sulfonylureas; additive glucose lowering could cause symptomatic hypoglycemia at taurine doses >=2 g/day

Evidence index

Promoted product-registry confidence score

Meta-analyses

Pooled human evidence

RCTs

192

Randomized clinical trials

Tracked studies

386

Studies currently mapped to this dossier

Free previewDossier openingDerived

Preview summary

Clinical opening brief

How this is sourcedDerived

This executive summary is generated by application logic from structured dossier evidence and safety fields.

Taurine is a Cardiovascular with its clearest current use in Type 2 diabetes mellitus and metabolic syndrome - glycemic, lipid, and inflammatory biomarker improvement.

High confidence human evidence supports the brief, anchored by 386 tracked studies, 24 meta-analyses, 192 RCTs and the most reliable movement in AST, TC, MDA.

Clinically meaningful in T2DM patients on insulin or sulfonylureas; additive glucose lowering could cause symptomatic hypoglycemia at taurine doses >=2 g/day Clinically meaningful in T2DM patients on insulin or sulfonylureas; additive glucose lowering could cause symptomatic hypoglycemia at taurine doses >=2 g/day

Free dossier previewResearch access

Research unlocks the working sections of the brief

The clinical opening stays public. Research opens the deeper evidence, biomarker, dosing, and PGx layers once you want the full operating brief.

Overview

Mechanism, safety, and scope

The opening memo leads into the working sections where the compound gets pressure-tested before it belongs in a real protocol.

Mechanism summary, safety framing, and evidence-scope caveats continue here.

Synergies, contradictions, and unresolved questions sit alongside the overview before the tables begin.

Reading path

From memo into tables

Evidence rows show trial design, outcome direction, grading, and the specific claims that survived synthesis.

Biomarker groups, dosing protocols, and PGx notes sit behind the next layer once you need operational detail.

Evidence

Graded study rows

Trial design, endpoint direction, and confidence cues.

Biomarkers

Grouped outcome maps

Human-linked markers, dosing context, and cluster summaries.

Dosing

Protocol context

Use-case-specific doses, duration, and practical notes.

PGx

Actionable modifiers

Genes, interactions, and what actually changes practice.

Biomarker and evidence layer

Highest-signal biomarkers, evidence rows, and claim-by-claim grading live here once the dossier graduates from opening memo to working brief.

Current public view: Dossier live. Full access reveals the actual operating tables.

Protocol detail

Dosing schedules, form choices, and practical timing are held back until the compound is worth operationalizing.

PGx modifiers and safety friction stay in the same layer so the protocol decision is made in one pass, not by guesswork.

Research unlockPreview

Evidence, biomarkers, dosing, and PGx stay behind the glass

You are already inside the dossier. Upgrade when you need the full working sections instead of only the opening memo.